Jaydess

Levonorgestrel, the active ingredient in Jaydess, is a Progestogen presented as a 13.5 µg/day intrauterine system (IUS) for intrauterine use. It releases levonorgestrel continuously to prevent pregnancy and to reduce menstrual blood loss in women of reproductive age.

GNH USA supplies Jaydess as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product meets EU regulatory standards and is distributed under strict quality‑assured conditions to qualified healthcare providers. Insertion must be performed by a trained clinician in a clinical setting.

Jaydess (levonorgestrel) acts within the hormonal contraceptive pathway to prevent pregnancy and to treat menstrual bleeding disorders.

- Contraception: provides long‑term, reversible birth control for up to three years. - Heavy menstrual bleeding: reduces menstrual blood loss and improves anemia associated with excessive bleeding. - Long‑term reversible contraception: offers a convenient, low‑maintenance option without daily dosing.

Levonorgestrel delivered via the intrauterine system may be associated with a range of adverse reactions.

Common Side Effects: - Irregular bleeding or spotting: unpredictable menstrual bleeding patterns, especially during the first months. - Amenorrhea: absence of menstrual periods after prolonged use. - Headache: mild to moderate tension‑type headaches. - Breast tenderness: transient discomfort or swelling of the breasts.

Serious or Rare Side Effects: - Pelvic inflammatory disease: infection that can affect the uterus, fallopian tubes, or ovaries. - Uterine perforation: rare event where the IUS breaches the uterine wall during insertion. - Ectopic pregnancy: pregnancy occurring outside the uterus, most commonly in the fallopian tube.

Before prescribing Jaydess, clinicians should consider several precautionary measures to ensure patient safety. - Contraindications: avoid use in women with active pelvic infection, unexplained vaginal bleeding, or known uterine anomalies. - Pregnancy testing: confirm the patient is not pregnant before insertion. - Follow‑up: schedule a check‑up 4–6 weeks after insertion to verify correct placement. - Medication interactions: be aware that enzyme‑inducing drugs may reduce efficacy. - Breastfeeding: discuss potential risks if the patient plans to breastfeed. - Store at ambient temperature: keep the device in its original packaging, protect from moisture and direct sunlight, and store below 25 °C.

Levonorgestrel released from an intrauterine system can interact with other medicines that affect hormone metabolism or uterine environment.

Major Interactions (Avoid): - Rifampicin and other strong enzyme inducers: may markedly lower levonorgestrel levels, reducing contraceptive effectiveness. - Antiepileptic drugs (e.g., carbamazepine, phenytoin): can increase hormone metabolism and compromise efficacy. - Antiretroviral therapy (e.g., efavirenz): may reduce levonorgestrel concentrations.

Moderate Interactions (Monitor Closely): - Hormonal therapies (e.g., estrogen‑containing contraceptives): may alter bleeding patterns when used concurrently. - NSAIDs: can increase the risk of breakthrough bleeding. - Antifungal azoles (e.g., ketoconazole): may modestly affect levonorgestrel metabolism.